Chronic application of MTII in a rat model of obesity results in sustained weight loss.

Hamilton BS, Doods HN

Obesity research1 Mar 2002Cited by 37 (Europe PMC)

PMID11886941DOI10.1038/oby.2002.28PepBankPUB-11886941

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mature female rats on normal chow, MTII reduced pellet intake in the first 2 weeks of treatment.
In plain wordsIn female rats on normal chow, MTII reduced food pellet intake in the first 2 weeks.
Peptide
Melanotan II
Outcome
DecreasePellet intake in first 2 weeks, chow-fed rats
Study
ratn: not reported in source
mature weight-stable female rats on cafeteria diet (HPF) or chow (RC)
Comparator
Saline
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 mg/kg per day · implanted mini-pump · minimally 28 daysAs given in this study (rat).
Source sentences
Summary
HPF rats and RC rats receiving MTII reduced their pellet intake and body weight in the initial 2 weeks of treatment (day 14, RC-saline: -1.6 +/- 1.8 g; RC-MTII, -22.5 +/- 3.7 g; HPF-saline, -7.1 +/- 1.7 g; HPF-MTII, -30.7 +/- 4.8 g).
1 context sentence(design, population, supporting numbers)
Summary · context
Mini-pumps delivering saline or MTII (1 mg/kg per day) for minimally 28 days were implanted.
Report a problemFND-1188694101
02AnimalAnimal study (in vivo)Efficacy outcome
In mature female rats on a highly palatable cafeteria diet, MTII reduced pellet intake in the first 2 weeks of treatment.
In plain wordsIn female rats on a cafeteria diet, MTII reduced food pellet intake in the first 2 weeks.
Peptide
Melanotan II
Outcome
DecreasePellet intake in first 2 weeks, highly palatable food rats
Study
ratn: not reported in source
mature weight-stable female rats on cafeteria diet (HPF) or chow (RC)
Comparator
Saline
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 mg/kg per day · implanted mini-pump · minimally 28 daysAs given in this study (rat).
Source sentences
Summary
HPF rats and RC rats receiving MTII reduced their pellet intake and body weight in the initial 2 weeks of treatment (day 14, RC-saline: -1.6 +/- 1.8 g; RC-MTII, -22.5 +/- 3.7 g; HPF-saline, -7.1 +/- 1.7 g; HPF-MTII, -30.7 +/- 4.8 g).
1 context sentence(design, population, supporting numbers)
Summary · context
Mini-pumps delivering saline or MTII (1 mg/kg per day) for minimally 28 days were implanted.
Report a problemFND-1188694102
03AnimalAnimal study (in vivo)Efficacy outcome
In mature female rats on normal chow, MTII reduced body weight in the first 2 weeks of treatment compared with saline.
In plain wordsIn female rats on normal chow, MTII led to more weight loss than saline in the first 2 weeks.
Peptide
Melanotan II
Outcome
DecreaseBody weight change at day 14, chow-fed rats
Study
ratn: not reported in source
mature weight-stable female rats on cafeteria diet (HPF) or chow (RC)
Comparator
Saline
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg/kg per day · implanted mini-pump · minimally 28 daysAs given in this study (rat).
Measurements
Body weight change at day 14
−22.5 g
RC-MTII
Body weight change at day 14
−1.6 g
RC-saline
Source sentences
Summary
HPF rats and RC rats receiving MTII reduced their pellet intake and body weight in the initial 2 weeks of treatment (day 14, RC-saline: -1.6 +/- 1.8 g; RC-MTII, -22.5 +/- 3.7 g; HPF-saline, -7.1 +/- 1.7 g; HPF-MTII, -30.7 +/- 4.8 g).
1 context sentence(design, population, supporting numbers)
Summary · context
Mini-pumps delivering saline or MTII (1 mg/kg per day) for minimally 28 days were implanted.
Report a problemFND-1188694103
04AnimalAnimal study (in vivo)Efficacy outcome
In mature female rats on a highly palatable cafeteria diet, MTII reduced body weight in the first 2 weeks of treatment compared with saline.
In plain wordsIn female rats on a cafeteria diet, MTII led to more weight loss than saline in the first 2 weeks.
Peptide
Melanotan II
Outcome
DecreaseBody weight change at day 14, highly palatable food rats
Study
ratn: not reported in source
mature weight-stable female rats on cafeteria diet (HPF) or chow (RC)
Comparator
Saline
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg/kg per day · implanted mini-pump · minimally 28 daysAs given in this study (rat).
Measurements
Body weight change at day 14
−30.7 g
HPF-MTII
Body weight change at day 14
−7.1 g
HPF-saline
Source sentences
Summary
HPF rats and RC rats receiving MTII reduced their pellet intake and body weight in the initial 2 weeks of treatment (day 14, RC-saline: -1.6 +/- 1.8 g; RC-MTII, -22.5 +/- 3.7 g; HPF-saline, -7.1 +/- 1.7 g; HPF-MTII, -30.7 +/- 4.8 g).
1 context sentence(design, population, supporting numbers)
Summary · context
Mini-pumps delivering saline or MTII (1 mg/kg per day) for minimally 28 days were implanted.
Report a problemFND-1188694104
05AnimalAnimal study (in vivo)Efficacy outcome
In mature female rats, pellet intake of MTII-treated animals returned to pre-implantation values after the initial treatment period.
In plain wordsIn female rats, food intake with MTII returned to its earlier level after the first weeks.
Peptide
Melanotan II
Outcome
No significant changePellet intake after the initial 2 weeks
Study
ratn: not reported in source
mature weight-stable female rats on cafeteria diet (HPF) or chow (RC)
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 mg/kg per day · implanted mini-pump · minimally 28 daysAs given in this study (rat).
Source sentences
Summary
Subsequently, pellet intake returned to pre-implantation values, although body weights remained reduced in both HPF and RC groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Mini-pumps delivering saline or MTII (1 mg/kg per day) for minimally 28 days were implanted.
Report a problemFND-1188694105
06AnimalAnimal study (in vivo)Efficacy outcome
In mature female rats on chow or highly palatable diet, body weights of MTII-treated animals remained reduced after food intake had returned to pre-implantation values.
In plain wordsIn female rats, body weight stayed lower with MTII even after food intake returned to normal.
Peptide
Melanotan II
Outcome
DecreaseBody weight after the initial 2 weeks
Study
ratn: not reported in source
mature weight-stable female rats on cafeteria diet (HPF) or chow (RC)
Comparator
Saline
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg/kg per day · implanted mini-pump · minimally 28 daysAs given in this study (rat).
Source sentences
Summary
Subsequently, pellet intake returned to pre-implantation values, although body weights remained reduced in both HPF and RC groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Mini-pumps delivering saline or MTII (1 mg/kg per day) for minimally 28 days were implanted.
Report a problemFND-1188694106
07AnimalAnimal study (in vivo)Efficacy outcome
In mature female rats, oxygen consumption was increased in rats treated with MTII.
In plain wordsIn female rats, MTII increased oxygen use, a sign of higher energy expenditure.
Peptide
Melanotan II
Outcome
IncreaseOxygen consumption
Study
ratn: not reported in source
mature weight-stable female rats on cafeteria diet (HPF) or chow (RC)
Comparator
Saline
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg/kg per day · implanted mini-pump · 17 daysAs given in this study (rat).
Source sentences
Summary
Oxygen consumption was increased in rats treated with MTII.
1 context sentence(design, population, supporting numbers)
Summary · context
Oxygen consumption was measured for 17 days in a second group of rats implanted with mini-pumps containing MTII (1 mg/kg per day) or saline.
Report a problemFND-1188694107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.